Skip to content
OpenCapital
Get started

Lineage Cell Therapeutics LCTX Q3 2025 earnings

Reported November 6, 2025 · After market close

Revenue$3.7MBeat by $1.7MDiluted EPS-$0.13Miss by $0.11
Revenue estimate$2.0M
EPS estimate-$0.02

Next report

Aug 11, 2026 (In 3 weeks)
Revenue estimate$1.8M
EPS estimate-$0.03

Versus estimates

Revenue

Q1 2026$1.7MMiss by $1.9MQ4 2025$6.6MBeat by $4.6M
Q3 2025$3.7MBeat by $1.7M
Q2 2025$2.8MBeat by $876.1KQ1 2025$1.5MMiss by $222.3KQ4 2024$2.9MBeat by $1.5M

Diluted EPS

Q1 2026-$0.03Miss by $0.01Q4 2025$0.00Beat by $0.05
Q3 2025-$0.13Miss by $0.11
Q2 2025-$0.01Beat by $0.01Q1 2025-$0.02In lineQ4 2024-$0.01Beat by $0.03

Ask the moment Lineage Cell Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Lineage Cell Therapeutics report Q3 2025 earnings?
Lineage Cell Therapeutics (LCTX) reported Q3 2025 earnings on November 6, 2025 after market close.
What were Lineage Cell Therapeutics's Q3 2025 revenue and EPS?
Lineage Cell Therapeutics reported revenue of $3.7M and diluted EPS of $-0.13 for Q3 2025.
Did Lineage Cell Therapeutics beat estimates in Q3 2025?
Revenue beat the consensus estimate of $2.0M by $1.7M. EPS missed the consensus estimate of $-0.02 by $0.11.
How did Lineage Cell Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 2.6% from $3.8M a year earlier and diluted EPS declined 550.0% from $-0.02.
Where can I find Lineage Cell Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-269534) and the 10-Q periodic report (0001193125-25-269599) directly on SEC EDGAR. The filing index links above go to sec.gov.